Compare prices and buy Cortagen from 6 research peptide vendors - also called suppliers or sources. Updated daily.
A synthetic tetrapeptide (Ala-Glu-Asp-Pro / AEDP, CAS 335591-03-2) in the Khavinson short-peptide family, which its developers list as a neuroprotector. Reported in Russian rat studies of chronic brain ischemia to speed behavioral recovery and limit lipid peroxidation in brain tissue. Not FDA-approved.
For research purposes only. Not medical advice.
Cortagen is a synthetic tetrapeptide, Ala-Glu-Asp-Pro (written AEDP), from Vladimir Khavinson's short-peptide program. The rest of the family is in Longevity and Bioregulators, where Cortagen sits with Epitalon and Pinealon among the pineal and central nervous system entries. PubChem's record for the peptide gives the formula C17H26N4O9 and a molecular weight of about 430, and lists both the name Cortagen and CAS 335591-03-2 among its synonyms.
The developers describe Cortagen as modeled on a brain extract. A 2004 paper co-authored by Khavinson says it was made by directed synthesis based on an amino-acid analysis of Cortexin, a peptide preparation from the brain cortex (Anisimov, Neuro Endocrinology Letters, 2004). In a 2001 paper, Khavinson reports that in organotypic cultures Cortagen stimulated the growth of explants from rat brain cortex, and reads this as a tissue-specific effect tied to the tissue whose peptides were used for its synthesis (Bulletin of Experimental Biology and Medicine, 2001).
The group's 2022 review in the International Journal of Molecular Sciences lists the tetrapeptide, spelled Korthagen, as a neuroprotector in its table of short peptides.
All of the work below is cell, tissue or animal research.
The developers' 2020 review of peptide-driven cell differentiation lists AEDP among the peptides that induce differentiation of pluripotent cells toward epidermis, mesenchyme and nervous tissue (Khavinson, Stem Cell Reviews and Reports, 2020).
As of October 21, 2026, ClinicalTrials.gov lists no study of Cortagen under the name or the sequence Ala-Glu-Asp-Pro.
A 2023 study tested Cortagen with three other short peptides on cultured lymphocytes from people aged 75 to 88, and reports that the peptides loosened condensed chromatin and activated ribosomal genes (Lezhava, Georgian Medical News, 2023). It is a laboratory study of donated cells.
PeptideScouter found no US regulatory record for Cortagen. As of October 21, 2026, it appears in none of these:
ClinicalTrials.gov lists no study of it under the name Cortagen or the sequence Ala-Glu-Asp-Pro as of October 2026, and the published experiments PeptideScouter found were run in animals and cultured cells. A 2023 study tested it on lymphocytes taken from people aged 75 to 88, which is a laboratory study of donated cells.
From its origin and from animal studies. A 2004 paper co-authored by its developer, Vladimir Khavinson, says the tetrapeptide Ala-Glu-Asp-Pro was made by directed synthesis based on an amino-acid analysis of Cortexin, a peptide preparation from the brain cortex. In a 2011 Russian study of rats with chronic brain ischemia, it sped recovery of disturbed behavior and prevented excessive lipid peroxidation in brain tissue. A 2000 study in rats reported faster growth and conduction in a regenerating sciatic nerve after a 10-day course. The developers' 2022 review lists it as a neuroprotector.
PeptideScouter found no US regulatory record for it. As of October 21, 2026, Cortagen does not appear in Drugs@FDA, in either table of FDA's Category 2 list of bulk drug substances raising significant safety risks, in FDA's lists of substances nominated for compounding under Sections 503A and 503B, or in the records of FDA's Pharmacy Compounding Advisory Committee meetings of October and December 2024 and July 2026. FDA's substance registry has no record of it, ClinicalTrials.gov lists no study of it and no FDA warning letter names it.
Kortagen and Korthagen are other spellings of Cortagen, the tetrapeptide Ala-Glu-Asp-Pro, and its developers' 2022 review table uses Korthagen. Cortexin is a different product, a polypeptide complex isolated from animal brain. Cortagen's developers say they designed its sequence from an amino-acid analysis of Cortexin.
Cortagen is sold by 6 research peptide vendors indexed on PeptideScouter, with 6 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
5 of the 6 indexed vendors currently have Cortagen in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Flawless Compounds currently lists Cortagen at $1.77/mg, the lowest listed price across 6 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $1.50/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 6 vendors listing Cortagen publish a PeptideScouter code, worth 10% to 15% off. Applied, the lowest effective price falls from $1.77/mg listed to $1.50/mg at Flawless Compounds. Each vendor's code is shown beside its price in the table above.
Cortagen ranges from $1.77/mg to $3.95/mg across 6 listings from 6 research peptide vendors, normalized to USD per milligram and refreshed daily.
6 research peptide vendors currently list Cortagen on PeptideScouter, with 5 in stock right now. We track 6 listings across size and kit variants.
Cortagen's CAS Registry Number is 335591-03-2.
